A Study in Healthy Subjects to Assess the Effect of Intragastric pH and Fasting on the Multiple-Dose Pharmacokinetics of AF-219

Trial Profile

A Study in Healthy Subjects to Assess the Effect of Intragastric pH and Fasting on the Multiple-Dose Pharmacokinetics of AF-219

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Gefapixant (Primary) ; Omeprazole
  • Indications Asthma; Cough; Interstitial cystitis; Musculoskeletal pain
  • Focus Pharmacokinetics
  • Sponsors Afferent Pharmaceuticals
  • Most Recent Events

    • 10 Mar 2015 Status changed from not yet recruiting to completed, according to ClinicalTrials.gov record.
    • 05 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top